Categories: Bulk Drug

Novartis board okays transfer of OTC business to GSK for Rs.109 cr

Mumbai, Jan 19, 2015  – Drugmaker Novartis India’s board of directors has approved the transfer of its over the counter (OTC) business to GlaxoSmithKline Consumer Pvt Ltd for Rs.109 crore.

The deal would be completed by October, subject to various regulatory approvals, Novartis told the stock exchange.

The development is a follow-through of a over $23 billion transaction that took place between the multinational drugmakers Novartis, GlaxoSmithKline and Eli Lilly, last April. The global deal awaits anti-trust and other regulatory approvals.

Global deal

As part of the global deal, GlaxoSmithKline’s cancer drugs segment was to move into Novartis’ fold for a consideration of $16 billion, even as vaccines moved out from Novartis and into GSK’s kitty for $7 billion.

But on the consumer healthcare front, Novartis and GSK were to create a joint venture company, where GSK was to have majority control with focus on wellness, oral health, nutrition and skin-care.

A GSK representative had said at the time of the global transaction that the deal did not include GSK’s consumer healthcare business in India. Novartis’ products including Voltarin, Excedrin and Otrivin move out to the joint venture.

In its statement, Novartis said, “Factors considered by the board in its consideration of the OTC transaction included, but were not limited to, the prospects for the company’s OTC business in India following the divestment of Novartis AG’s global OTC business, including all of Novartis AG’s major OTC patents, trademarks and R&D assets; the valuation for the transfer of the OTC Division ; and the enhanced ability of the board, the company’s management and all retained employees to focus on the growth of the company’s retained businesses.”

The Pharma Times News Bureau

Recent Posts

8 Ways Insomnia Affects Skin Health & How To Avoid It

By Dr. Priyanka Kuri, Consultant - Dermatology, Aster Whitefield Hospital, Bengaluru Insomnia, the persistent inability…

1 day ago

Breaking New Ground in Migraine Care: A Landmark Session on Diagnosis and Treatment

Illuminating Latest Advances in Migraine Diagnosis and Treatment New Delhi, December 21, 2024: In a…

1 day ago

Healthcare Startups to Watch Out for in 2025

New Delhi, December 20, 2024: The healthcare sector is undergoing a transformation fueled by technological…

2 days ago

DKMS’s First Global Impact Report of 2023 Serves as New Ray of Hope for Blood Cancer Patients Worldwide

National, December 20, 2024: DKMS just published its first Global Impact Report that outlines the organization's…

2 days ago

Sterling Biotech to start world’s first precision fermentation-based dairy protein factory in Gujarat

Ahmedabad, December 19, 2024: Sterling Biotech Limited, a joint venture between Perfect Day and Zydus, has…

3 days ago

Pioneers in Senior Care, Antara, Partners with Leading Diagnostics Player Dr. Lal PathLabs to Strengthen its Geriatric Care Services

New Delhi, December 19, 2024: Antara Senior Care, an integrated eco-system provider for lifestyle and…

3 days ago